You just read:

Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

News provided by

Vanda Pharmaceuticals Inc.

May 13, 2020, 07:00 ET